SCHEMBL16572891

SCHEMBL16572891

C[C@@H](O)C(=O)[C@@H]1CNc2nc(N)[nH]c(=O)c2N1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS1 P29475 10/20 0.64
▸ CASP7 P55210 2/20 0.64
▸ HSD17B10 Q99714 2/20 0.64
▸ USP2 O75604 1/20 0.64
▸ KDM4E B2RXH2 2/20 0.62
▸ MAPT P10636 2/20 0.62
▸ BLM P54132 2/20 0.62
▸ KMT2A Q03164 2/20 0.62
▸ ALDH1A1 P00352 1/20 0.62
▸ GLA P06280 1/20 0.62
▸ HPGD P15428 1/20 0.62
▸ PMP22 Q01453 1/20 0.62
▸ NPSR1 Q6W5P4 1/20 0.62
▸ TDP1 Q9NUW8 1/20 0.62
▸ PAH P00439 1/20 0.54
▸ NOS3 P29474 3/20 0.52
▸ NOS2 P35228 3/20 0.52
▸ MEN1 O00255 1/20 0.45
▸ RGS12 O14924 1/20 0.45
▸ LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1858785 1.00 NOS1 (0.64) NOS1CASP7HSD17B10USP2KDM4E
SCHEMBL16572883 1.00 NOS1 (0.64) NOS1CASP7HSD17B10USP2KDM4E
SCHEMBL16564266 1.00 NOS1 (0.64) NOS1CASP7HSD17B10USP2KDM4E
SCHEMBL16572892 1.00 NOS1 (0.64) NOS1CASP7HSD17B10USP2KDM4E
SCHEMBL16564323 1.00 NOS1 (0.64) NOS1CASP7HSD17B10USP2KDM4E
SCHEMBL20375021 1.00 NOS1 (0.64) NOS1CASP7HSD17B10USP2KDM4E
SCHEMBL19410958 0.82 NOS1 (0.59) NOS1CASP7HSD17B10USP2KDM4E
SCHEMBL188413 0.82 NOS1 (0.56) NOS1CASP7HSD17B10USP2KDM4E
SCHEMBL20375133 0.81 NOS1 (0.58) NOS1CASP7HSD17B10USP2KDM4E
SCHEMBL20374993 0.81 NOS1 (0.58) NOS1CASP7HSD17B10USP2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181254-B2 Method for producing sepiapterin and tetrahydrolactoylpterin SHIRATORI PHARMACEUTICAL CO., LTD. (JP) 2015-11-10 — — US disclosed
US-20150119574-A1 METHOD FOR PRODUCING SEPIAPTERIN AND TETRAHYDROLACTOYLPTERIN SHIRATORI PHARMACEUTICAL CO., LTD. (JP) 2015-04-30 — — US disclosed
EP-2848619-A1 METHOD FOR PRODUCING SEPIAPTERIN AND TETRAHYDROLACTOYLPTERIN Shiratori Pharmaceutical Co., Ltd. (JP) 2015-03-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119574-A1 METHOD FOR PRODUCING SEPIAPTERIN AND TETRAHYDROLACTOYLPTERIN SPR, HPN, RNPEP NOS1 1438/4885CASP7 1605/4885HSD17B10 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback